iCAD,
Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image
analysis, workflow solutions and radiation therapy for the early
identification and treatment of cancer, today announced that the Company
will be participating in the 12th Annual Needham Healthcare
Conference being held from April 30-May 1, 2013 at the Westin Grand
Central Hotel in New York. Ken Ferry, iCAD’s President and CEO, will
deliver a corporate overview on April 30th at 12:10 p.m.
A live webcast of Mr. Ferry’s presentation can be accessed by visiting
the investors section of the Company’s website at www.icadmed.com.
A replay of the webcast will be archived on the iCAD website for 90 days
following the presentation.
About iCAD, Inc.
iCAD is a leading provider of advanced image analysis, workflow
solutions and radiation therapies for the early identification and
treatment of common cancers. iCAD offers a comprehensive range of
high-performance, upgradeable CAD solutions for mammography and advanced
image analysis and workflow solutions for Magnetic Resonance Imaging,
for breast and prostate cancers and Computed Tomography for colorectal
cancer. iCAD’s Xoft System, offers radiation treatment for early-stage
breast cancer that can be administered in the form of intraoperative
radiation therapy or accelerated partial breast irradiation. The Xoft
System is also cleared for the treatment of non-melanoma skin cancer,
cervical cancer and endometrial cancer. For more information, call
877-iCADnow, or visit www.icadmed.com.
"Safe Harbor" Statement under the Private Securities Litigation
Reform Act of 1995:
Certain statements contained in this News Release constitute
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements involve a number of known and unknown risks, uncertainties
and other factors which may cause the actual results, performance or
achievements of the Company to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Such factors include, but are not limited
to, the Company’s ability to defend itself in litigation matters, the
Company’s ability to identify a replacement for the Axxent FlexiShield
Mini, the risks relating to the Company’s acquisition of Xoft including,
the expected benefits of the acquisition may not be achieved in a timely
manner, or at all; the Xoft business operations may not be successfully
integrated with iCAD’s and iCAD may be unable to achieve the expected
synergies, business and strategic objectives following the transaction,
the risks of uncertainty of patent protection; the impact of supply and
manufacturing constraints or difficulties; product market acceptance;
possible technological obsolescence; increased competition; customer
concentration; and other risks detailed in the Company’s filings with
the Securities and Exchange Commission. The words “believe”,
“demonstrate”, “intend”, “expect”, “estimate”, “anticipate”, “likely”,
and similar expressions identify forward-looking statements. Readers are
cautioned not to place undue reliance on those forward-looking
statements, which speak only as of the date the statement was made. The
Company is under no obligation to provide any updates to any information
contained in this release. For additional disclosure regarding
these and other risks faced by iCAD, please see the disclosure contained
in our public filings with the Securities and Exchange Commission,
available on the Investors section of our website at http://www.icadmed.com
and on the SEC’s website at http://www.sec.gov.
